Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Total 13F shares
-
10,623,066
-
Share change
-
+320,978
-
Total reported value
-
$33,463,045
-
Price per share
-
$3.15
-
Number of holders
-
52
-
Value change
-
+$1,179,405
-
Number of buys
-
15
-
Number of sells
-
15
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q2 2023
As of 30 Jun 2023 Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) had 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 10,623,066 shares of stock of the company.
Largest 10 holders included Bain Capital Life Sciences Investors, LLC, Artal Group S.A., Avidity Partners Management LP, Flagship Pioneering Inc., Samsara BioCapital, LLC, CHI Advisors LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, DAFNA Capital Management LLC, and Omega Fund Management, LLC.
This table shows 52 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.